Ventyx Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 192.96 million compared to USD 108.43 million a year ago. Basic loss per share from continuing operations was USD 3.3 compared to USD 2.07 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.73 USD | -5.02% | +15.65% | +91.50% |
05-16 | Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise | MT |
05-16 | Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.50% | 333M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- VTYX Stock
- News Ventyx Biosciences, Inc.
- Ventyx Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023